Synthesis of Platinum Nanocrystals within Iodine Ions Mediated

A liquid-phase reducing method of synthesizing Pt nanocrystals was demonstrated, and dendrite-, cube-, and cuboctahedron-shaped Pt nanocrystals (NCs) with well-defined monomorphic were successfully synthesized through iodine ions mediated with the CTAB agent. When the KI concentration was increased to thirty times of K2PtCl4 at the nucleation stage, the high-quality Pt nanodendrites could be obtained. However, no matter how many KI were added at the growth age, only cube- and cuboctahedron-shaped Pt nanocrystals formed. The results of high-resolution TEM, EDX, and XRD indicated that the size and shape of Pt NCs could be turned by changing the concentration and time of KI. In the nucleation stage, it might be due to that some iodine ions adsorb on the surfaces of Pt NCs, which probably cause the rapid growth process resulting in the formation of Pt nanodendrites. In the growth stage, although high concentrations of I− ions could contribute to the shape control and generate bigger particles of Pt NCs, small Pt particles do not grow into dendrites. The insight into the role of I− ions in synthesis of Pt NCs reported here provided a viewpoint for clearly understanding the formation mechanism of anisotropic platinum nanostructures

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Objective Robust biomarker predicting efficacy of immunotherapy is limited. Circulating tumor DNA (ctDNA) sought to effectively monitor therapeutic response as well as disease progression. This study aims to investigate predictive role of ctDNA short-term dynamic change (6 weeks postimmunotherapy) in a single-arm, phase 2 trial of sintilimab plus docetaxel for previously treated advanced non-small cell lung cancer (NSCLC) patients.Methods A total of 33 patients with advanced NSCLC with disease progression during or after any first-line treatment were prospectively enrolled between 2019 and 2020. Patients received sintilimab (200 mg, day 1, every 3 weeks) plus docetaxel (75 mg/m2, day 3, every 3 weeks) for 4–6 cycles, followed by maintenance therapy with sintilimab (200 mg, day 1, every 3 weeks) until disease progression or unacceptable toxic effects. Blood samples were prospectively collected at baseline, and after 2 cycles of treatment (6 weeks post-treatment). All samples were subjected to targeted next-generation sequencing with a panel of 448 cancer-related genes. The landscape of high-frequency genomic profile of baseline and 6th week was described. Major molecular characteristics in preselected genes of interest associated with response to second-line chemoimmunotherapy were analyzed. The curative effects and prognosis of patients were evaluated.Results Patients with ctDNA clearance at 6th week had decreased tumor volume, while most patients with positive ctDNA at 6th-week experienced an increase in tumor volume. Positive 6th-week ctDNA was associated with significantly shorter progression-free survival (PFS) (91 vs NR days; p<0.0001) and overall survival (47 vs 467 days; p =0.0039). Clearance of clonal mutations and none new clonal formation at 6th week were associated with longer PFS (mPFS 89 vs 266 days, p =0.003). ctDNA clearance at 6th week was an independent risk factor for progression or death (HR=100 (95% CI 4.10 to 2503.00), p=0.005).Conclusion ctDNA status and ctDNA mutation clearance putatively serve as predictive biomarkers for sintilimab combined with docetaxel chemotherapy in pretreated advanced NSCLC patients